<DOC>
	<DOCNO>NCT00125853</DOCNO>
	<brief_summary>The purpose study conduct randomise trial compare insulin sensitivity , 24 hour blood pressure profile , tolerability nebivolol plus thiazide-like diuretic versus atenolol plus thiazide-like diuretic .</brief_summary>
	<brief_title>The Effect Nebivolol Insulin Sensitivity</brief_title>
	<detailed_description>Retrospective study treat hypertensive cohort strongly implicate beta blocker therapy increase risk develop new-onset diabetes . This lead late British Hypertension Society guideline advise caution use beta blocker particularly combination thiazide-like diuretic . However National Institute Clinical Excellence recommend beta-blocker + thiazide combination treatment choice patient increase risk develop diabetes . Nebivolol new class beta blocker . Some study diabetic hypertensive patient suggest nebivolol impair insulin sensitivity . The aim study compare effect insulin sensitivity nebivolol versus atenolol , combination thiazide-like diuretic , group non-diabetic hypertensive patient .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>Males female age Blood pressure meet three follow criterion : Systolic blood pressure ( SBP ) &lt; = 160 diastolic blood pressure ( DBP ) &lt; = 90 one antihypertensive drug ; OR SBP &lt; = 140 DBP &lt; = 85 two antihypertensive drug ; OR SBP 140170 DBP 90100 antihypertensive drug . Compelling indication treatment beta blocker Contraindication , previous history , major intolerance treatment beta blocker thiazidelike diuretic Any condition interfere treatment patient 's ability complete study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>blood pressure</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>beta blocker</keyword>
	<keyword>randomise double blind crossover trial</keyword>
</DOC>